Related Experiment Videos
Azathioprine for treating rheumatoid arthritis
M E Suarez-Almazor1, C Spooner, E Belseck
1Health Services Research, Veterans Affairs Medical Center, Mailbox Station 152, 2002 Holcombe Blvd, Houston, Texas, USA, 77024. mes@bcm.tmc.edu
The Cochrane Database of Systematic Reviews
|October 18, 2000
Summary
Azathioprine shows short-term benefits for rheumatoid arthritis joint pain but has higher toxicity. Due to a high risk-benefit ratio and limited data, it is not recommended over other disease-modifying anti-rheumatic drugs.
Area of Science:
- Rheumatology
- Clinical Pharmacology
Background:
- Rheumatoid arthritis (RA) is a chronic autoimmune disease causing joint inflammation and damage.
- Disease-modifying anti-rheumatic drugs (DMARDs) are used to manage RA, but their efficacy and safety profiles vary.
Purpose of the Study:
- To evaluate the short-term efficacy and safety of azathioprine in treating rheumatoid arthritis.
- To compare azathioprine's effects against placebo in RA patients.
Main Methods:
- Systematic review and meta-analysis of randomized controlled trials (RCTs) and controlled clinical trials.
- Searched Cochrane Musculoskeletal Group, Cochrane Controlled Trials Register, Medline, and Embase databases.
- Extracted data on efficacy (joint counts, pain, function, ESR) and toxicity (adverse reactions, withdrawals) at six-month endpoints.
Main Results:
- Three trials with 81 patients compared azathioprine to placebo.
- Azathioprine demonstrated a statistically significant benefit in reducing tender joint scores (SMD -0.98; 95% CI -1.45, -0.50).
- Withdrawals due to adverse reactions were significantly higher in the azathioprine group (OR 4.56; 95% CI 1.16, 17.85).
Conclusions:
- Azathioprine offers a significant short-term benefit for joint disease activity in RA patients.
- Evidence is limited by small sample sizes and older trial data, with no assessment of long-term outcomes.
- Higher toxicity compared to other DMARDs suggests azathioprine should not be recommended over alternatives due to its risk-benefit profile.